

BioCity invests in early-stage precision medicine biotech

29 August 2019 | News

Kinomica Ltd has already worked in collaboration with big pharma, successfully applying its kinase analysis withonmarket drugs



BioCity, the pioneering life science incubator and business collective, has announced investment in precision medicine biotech, Kinomica Ltd., via the Innovate UK Precision Medicine Investment Accelerator.

Spun out from Barts Cancer Institute, Queen Mary University of London, Kinomica Ltd is an early stage precision medicine biotech developing novel technologies for companion diagnostics (CDx) and therapeutic development in precision medicines.

Graduates of the BioCity Accelerator and now based at Alderley Park, Kinomica Ltd have developed a powerful suite of advanced proprietary bioinformatics and phosphoproteomic analytical methods, that allows the direct measurement of multiple endogenous kinases.

Flagship innovation, KinoScan[™] will focus on the field of oncology, working in collaboration with pharma to improve the monitoring of drug efficacy and response, and for the discovery of novel biomarkers to aid patient stratification and support superior clinical trial performance. Although initially focused on oncology, KinoScan[™] has potential applications in other therapeutic areas such as autoimmune diseases, rheumatoid arthritis and neurological diseases.

Kinomica Ltd has already worked in collaboration with big pharma, successfully applying its kinase analysis with on-market drugs. The development of companion diagnostics and the advancement of precision medicine is a key priority for the UK government.

This is the latest investment announcement by BioCity, which is increasingly positioning itself as a leading life science investor.

To date, BioCity has made investments in twenty-nine life science ventures. BioCity specialises in seed funding via

convertible loans for very early stage ventures and co-investment in growing life science ventures.